Lupus

• View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
  In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
• Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
• This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
• “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

• The review acknowledges women with disability face barriers to access support and efforts to understand their experiences need to be accelerated.
• As part of review feedback, key disability organisations said a gender strategy was needed.
• Yet the final recommendations remain largely silent on gender, despite overwhelming gender inequality in the NDIS.

To uphold women’s right to safety

• Only three out of the 222 disability royal commission recommendations explicitly focus on women.
• Read more:
  Unregistered NDIS providers are in the firing line – but lots of participants have good reasons for using them

To support women as participants, as well as carers

• Women are also over-represented as carers for people with disability.
• Half of all NDIS participants are children and nearly 90% of primary carers for children are women.
• Women are highly successful advocates for their children.

To stop reproducing medical bias

• NDIS assessments rely on evidence from health-care professionals, which means the NDIS likely reproduces the gender biases of the medical system.
• How the NDIS review could help people with psychosocial disability

  Many chronic conditions experienced predominantly by women can have fluctuating symptoms.

• These conditions – and others that get worse over time – can significantly escalate without appropriate daily living supports.

To close access gaps

• The fresh NDIS review echoes previous reviews that found gaps and ambiguity between the NDIS and health systems.
• New agreements with states announced prior to the review similarly lack attention to gender, so there is no assurance women trying to access support outside the NDIS won’t continue to face the same barriers.

More detailed data would be a good start

• The cycle of applying and re-applying is a heavy administrative and emotional burden, disproportionately shouldered by women.
• Collecting more detailed data about participants “disaggregated by gender and sexuality” is listed in the review’s recommendations.

• Diana Piantedosi works for Women with Disabilities Victoria (WDV) and is also a member of the Victorian Disability Advisory Council (VDAC), Victorian NDIS Community Advisory Council (VCAC) and DFFH's LGBTIQA+ Disability Inclusion Expert Advisory Group.
• Lena Molnar works for Women with Disabilities Victoria (WDV).

• Antibody Based Therapeutics Market is projected to reach USD 364180 Million in 2029, increasing from USD 175410 Million in 2022, with a CAGR of 11.0% during the period of 2023 to 2029.
• The medical community's rising acceptance of antibody therapies is partly due to their expanding applicability, particularly in cancer and autoimmune illnesses.
• The market for antibody therapies is expanding due to the rising incidence of chronic illnesses worldwide.
• The Market for Antibody Therapeutics is dominated by North America because of the region's strong healthcare system, intensive R&D, and high rate of chronic illness.

• ET
  WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
• Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
• KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
• Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.